23andMe Appoints Andy Page as President
June 11, 2013
Internet Veteran and 23andMe Board Member Named to Executive Leadership Role as Company Pursues Customer Growth, Sector Leadership
Mountain View, Calif. – June 11, 2013 – 23andMe, the leading personal genetics company, today announced that it has appointed Internet veteran and 23andMe board member Andy Page as the company’s president, a newly created senior executive position. Page will report to CEO and Co-Founder Anne Wojcicki. Page, who has been a member of the 23andMe board of directors since 2012, joins the company’s executive leadership with dedicated oversight of the company’s strategy and operations, while Wojcicki will lead its research organization and shape its long-term vision. “Today’s announcement broadens the management team and reflects both our extraordinary growth and future ambitions,” Wojcicki said. “Several months ago, we announced a goal of attracting one million customers by the end of 2013. I believe this goal is a stepping-stone for empowering even more individuals to take greater control of their health through personal genetics. Looking to 2014 and beyond, I see the need to focus on this vision for the future as well as our business strategy to ensure the company scales effectively. “Andy is exactly the kind of business leader we need to achieve these goals,” Wojcicki added. “He has a well-established track record of creating successful business strategies, identifying market opportunities and configuring operational structures that optimize companies’ long-term growth potential. The fact that Andy has achieved such success in a broad range of companies within the Internet sector is uniquely advantageous to us. I’m very pleased that 23andMe will be his next platform for success.” Effective June 12, 2013, Page will assume responsibility for the company’s product and engineering, marketing, finance, business development, laboratory operations and legal/regulatory affairs functions. In addition, he will play a critical role in further developing the company’s business strategy and identifying opportunities for long-term growth and industry leadership. Page also will remain a board member. Wojcicki, who also is a member of the company’s board, will focus her management responsibilities in heading the company’s research organization as it continues to pursue important new medical discoveries using the company’s one-of-a-kind, crowd-sourced research model and shaping the company’s long-term vision as a transformative force in personalized medicine and its role as a pioneer in the field of genomic medicine. She also will work closely with Page on business strategy. “My role on the board has provided a detailed view of the enormous potential of 23andMe,” Page said. “This company can be transformative on a global scale, making personalized medicine and real-time research a reality. The company has made significant progress in achieving its potential, and working with Anne and the rest of the 23andMe team I look forward to building a successful company that improves health care and advances understanding of the human genome.” Page previously served as president of Gilt Groupe, an online luxury shopping destination, where he oversaw the company’s various businesses and operations including Women’s, Men’s, Kids & Baby, Home, Park & Bond, Gilt City and Gilt Taste. He joined Gilt in April 2010 as its chief financial officer and became its president in 2011. Prior to joining Gilt, Page was chief operating and financial officer at PlayPhone, Inc., where he was responsible for managing the company’s multinational operations. Before PlayPhone, he was chief financial officer and SVP of business strategy of StubHub Inc. There he managed the company’s financial operations, business strategy, financial reporting, and administrative functions. He led the company’s sale to eBay in 2007. Page also has held senior executive positions at Panasas Inc., ONI Systems Corp., and Robertson Stephens & Company. Page holds a bachelor of arts degree from Princeton University and a master of business administration from Harvard Business School. He is an advisor to several private e-commerce companies. He also serves on the board of directors of My New Red Shoes, a nonprofit organization that provides back-to-school clothes for homeless and low-income children in the San Francisco Bay Area.
23andMe, Inc., headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA clearances for genetic health reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80% of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. More information is available at www.23andMe.com.